Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

Journal of Cutaneous Pathology

Volumn 40, Issue 7, 2013, Pages 667-669

  Kim, Gene H ^a,b,d   Levy, Alan ^c   Compoginis, Goli ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Levy Dermatology   (United States)

^d not available   (United States)

Author keywords

drug reaction; melanoma; panniculitis; vemurafenib

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE; VEMURAFENIB;

AMINO ACID SUBSTITUTION; CASE REPORT; CHEMICALLY INDUCED; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; MISSENSE MUTATION; PANNICULITIS; PATHOLOGY; ARTICLE; CHEMICALLY INDUCED DISORDER;

AMINO ACID SUBSTITUTION; FEMALE; HUMANS; INDOLES; MELANOMA; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM METASTASIS; PANNICULITIS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84879174963     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12149     Document Type: Article

References (11)

1. Hocker TL, Singh MK, Tsao H,. Melanoma Genetics and Therapeutic Approaches in the 21st Century: moving from the benchside to the bedside. J Invest Dermatol 2008; 128: 2575.
2. Dutton-Regester K, Hayward NK,. Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell Melanoma Res 2012; 25: 144.
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med 2011; 364: 2507.
4. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Eng J Med 2010; 363: 809.
5. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitory of oncogenic mutant BRAF kinase, in patients with metastatic melanoma an other solid tumors [abstract 8503]. J Clin Oncol 2010; 28 (15s Suppl).
6. Ribas A, Kim KB, Shuchter LM, et al. Brim-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma [abstract 8509]. J Clin Oncol 2011; 29 (Suppl).
7. Zimmer L, Livingstone E, Hillen U, Dömkes S, Becker A, Schadendorf D,. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012; 148: 357.
8. Monfort JB, Pagès C, Schneider P, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 2012; 5: 399.
9. Jagedo J, Campbell R, Long T, Muglia J, Telang G, Robinson-Bostom L,. Sweet's syndrome-like neutrophilic lobular panniculitis associated with all-trans-retinoic acid chemotherapy in a patient with acute promyelocytic leukemia. J Am Acad Dermatol 2007; 56: 690.
10. Ball NJ, Cowan BJ, Hashimoto SA,. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases. J Cutan Pathol 2009; 26: 331.
11. Hasegawa M, Sato S, Nakada M, et al. Sweet's syndrome associated with granulocyte colony-stimulating factor. Eur J Dermatol 1988; 8: 503.